A Phase 3 interventional study of HX575 recombinant human erythropoietin alfa and ERYPO in Anemia and Chronic Renal Insufficiency, sponsored by Sandoz. Terminated at 123 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-05.
Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing Epoetin Alfa in Anemia — 2 open to participants now, 3 under way, 2 of them phase 3. Epoetin Alfa · Anemia.
Among the 126 studies testing Epoetin Alfa in Anemia, this one is the 14th largest by enrollment of the 112 interventional ones that give a count, is one of 5 that started in 2007, is one of 45 in phase 3, and was the 101st registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →2 of the 126 studies testing Epoetin Alfa in Anemia are open now, in 1 country. Recruiting first, the newest first:
Services Hospital, Lahore · Sites in Pakistan
Ages 18–65
Geoff Block
Ages 18+
By country, each count listing its studies:
Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 45 · Phase 3 46 · Phase 4 20
First in 1988; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 337 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 71 across the 112 interventional studies. Of the 114 that completed or were terminated, 23 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
95 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sandoz, one of the names counted as Novartis. Under that name alone:
Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
19 studies in Anemia by Novartis: 1 open now, 2 under way, 2 of them phase 3. Of 16 finished, 11 (69%) have results posted.
Among the 19 studies in Anemia by Novartis, this one is the 5th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2007, is one of 12 in phase 3, and was the 6th registered.
Novartis’s Anemia studies by the year they started, since 2004.
2 of the studies testing Epoetin Alfa in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07565701Phase 3Geoff BlockSafety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis | 2027-04 |
| NCT07755683Services Hospital, LahoreEffect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing Dialysis | 2027-02-28 |
Add all 2 to your calendar (.ics) → With an account.
Among the 126 studies testing Epoetin Alfa in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 19 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, controlled, double-blind, multicenter multinational safety study involving about 300 predialysis patients aged 18 years or above suffering from anemia.
Symptomatic anemia will be corrected by s.c. application of EPO HEXAL or ERYPO® in order to achieve a hemoglobin target range of 10.0 -12.0 g/dL.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HX575, EPO HEXAL
Drug: HX575 recombinant human erythropoietin alfa
ERYPO
Drug: ERYPO
Solution for injection (s.c.)
Solution for injection (s.c.)
Change in Hemoglobin Level
Mean absolute change in hemoglobin (baseline to end of study week 13)
Time frame: 13 weeks
Weekly Epoetin Dose
Mean weekly epoetin dose \[IU/kg\] in study weeks 11-13
Time frame: weeks 11-13
Immunogenicity
Number of participants with antibody formation against Epoetin during treatment period (safety set)
Time frame: 13 weeks
| Milestone | HX575, EPO HEXAL | ERYPO |
|---|---|---|
| Started | 174 | 163 |
| Completed | 37 | 29 |
| Not completed | 137 | 134 |
| Milestone | HX575, EPO HEXAL | ERYPO |
|---|---|---|
| Started | 151 | 119 |
| Completed | 144 | 112 |
| Not completed | 7 | 7 |
Mean absolute change in hemoglobin (baseline to end of study week 13)
| g/dL | HX575, EPO HEXAL | ERYPO |
|---|---|---|
| Change in Hemoglobin Level | 2.2 ± 1.0 | 2.1 ± 1.2 |
Mean weekly epoetin dose \[IU/kg\] in study weeks 11-13
| IU/kg | HX575, EPO HEXAL | ERYPO |
|---|---|---|
| Weekly Epoetin Dose | 55.1 ± 41.9 | 57.9 ± 46.6 |
Number of participants with antibody formation against Epoetin during treatment period (safety set)
| participants | Treatmen HX575 EPO HEXAL | Treatment ERYPO |
|---|---|---|
| Immunogenicity | 5 | 2 |
Collected over Treatment period: up to 1 year; Safety follow up period: 6 months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment HX575, EPO HEXAL | 6/174 (3.4%) | 50/174 (28.7%) | 137/174 (78.7%) |
| Treatment ERYPO | 14/163 (8.6%) | 70/163 (42.9%) | 132/163 (81%) |
| Safety Follow-up HX575, EPO HEXAL | 2/151 (1.3%) | 22/151 (14.6%) | 87/151 (57.6%) |
| Safety Follow-up ERYPO | 1/119 (0.8%) | 24/119 (20.2%) | 58/119 (48.7%) |
| Event | Treatment HX575, EPO HEXAL | Treatment ERYPO | Safety Follow-up HX575, EPO HEXAL | Safety Follow-up ERYPO |
|---|---|---|---|---|
| Renal failure chronicRenal and urinary disorders | 12/174 | 22/163 | 11/151 | 10/119 |
| Renal impairmentRenal and urinary disorders | 2/174 | 7/163 | 1/151 | 1/119 |
| Renal failureRenal and urinary disorders | 7/174 | 6/163 | 2/151 | 2/119 |
| PneumoniaInfections and infestations | 2/174 | 4/163 | 1/151 | 0/119 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/174 | 4/163 | 1/151 | 0/119 |
| Cardiac failureCardiac disorders | 4/174 | 3/163 | 0/151 | 0/119 |
| AzotaemiaRenal and urinary disorders | 3/174 | 3/163 | 1/151 | 1/119 |
| DehydrationMetabolism and nutrition disorders | 0/174 | 3/163 | 0/151 | 0/119 |
| Cerebrovascular accidentNervous system disorders | 1/174 | 3/163 | 1/151 | 0/119 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 3/174 | 0/163 | 2/151 | 0/119 |
| Event | Treatment HX575, EPO HEXAL | Treatment ERYPO | Safety Follow-up HX575, EPO HEXAL | Safety Follow-up ERYPO |
|---|---|---|---|---|
| HypertensionVascular disorders | 38/174 | 41/163 | 10/151 | 10/119 |
| Renal failure chronicRenal and urinary disorders | 13/174 | 24/163 | 13/151 | 11/119 |
| Oedema peripheralGeneral disorders | 21/174 | 17/163 | 4/151 | 2/119 |
| NasopharyngitisInfections and infestations | 17/174 | 14/163 | 5/151 | 2/119 |
| Urinary tract infectionInfections and infestations | 16/174 | 12/163 | 5/151 | 6/119 |
| HypoglycaemiaMetabolism and nutrition disorders | 3/174 | 11/163 | 2/151 | 0/119 |
| FatigueGeneral disorders | 10/174 | 1/163 | 3/151 | 0/119 |
| BronchitisInfections and infestations | 8/174 | 9/163 | 3/151 | 1/119 |
| Renal impairmentRenal and urinary disorders | 3/174 | 9/163 | 1/151 | 2/119 |
| VomitingGastrointestinal disorders | 3/174 | 8/163 | 0/151 | 0/119 |
| Age, Continuous(years) | Treatmen HX575 EPO HEXAL | Treatment ERYPO | Total |
|---|---|---|---|
| Mean | 64.1 ± 14.4 | 64.9 ± 15 | 64.5 ± 14.7 |
| Sex: Female, Male(Participants) | Treatmen HX575 EPO HEXAL | Treatment ERYPO | Total |
|---|---|---|---|
| Female | 97 | 98 | 195 |
| Male | 77 | 65 | 142 |
| Race (NIH/OMB)(Participants) | Treatmen HX575 EPO HEXAL | Treatment ERYPO | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 6 | 7 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 167 | 155 | 322 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Region of Enrollment(participants) | Treatmen HX575 EPO HEXAL | Treatment ERYPO | Total |
|---|---|---|---|
| Austria | 4 | 1 | 5 |
| Czech Republic | 22 | 19 | 41 |
| Russian Federation | 29 | 24 | 53 |
| Romania | 47 | 52 | 99 |
| Poland | 13 | 14 | 27 |
| Slovakia | 4 | 3 | 7 |
| Bulgaria | 4 | 4 | 8 |
| France | 0 | 1 | 1 |
| Germany | 45 | 39 | 84 |
| India | 6 | 6 | 12 |
Showing the first 100 of 123 sites across 10 countries. Choose a country and city above to see the rest.
The record gives a start of Sep 2007, a primary completion of Jul 2009 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2018, 8 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epoetin Alfa